Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AAVB 039

Next Previous
Drug Profile

AAVB 039

Alternative Names: AAV.ABCA4.intein; AAV8.ABCA4; AAVB-039; Dual adeno-associated virus based Stargardt disease gene therapy - AAVantgarde

Latest Information Update: 08 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AAVantgarde Bio
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action ATP binding cassette transporter subfamily A member 4 replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Stargardt disease

Most Recent Events

  • 05 Oct 2026 Pharmacodynamics and adverse events data from a preclinical study in Stargardt disease released by AAVantgarde Bio
  • 29 Sep 2026 Phase-I/II clinical trials in Stargardt disease (In adolescents, In children, In adults) in Norway (Subretinal) (NCT07161544)
  • 02 Oct 2025 AAVB 039 receives Orphan Drug status for Stargardt disease in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top